Fox Run Management, L.L.C. Viking Therapeutics, Inc. Transaction History

Fox Run Management, L.L.C.

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 10, 2022	SELL	$3.0 - $4.88 $33,597 - $54,651	-11,199 Closed	0 $0
Q4 2021 Feb 09, 2022	BUY	$4.6 - $6.72 $51,515 - $75,257	11,199 New	11,199 $52,000
Q1 2019 Oct 17, 2019	SELL	$7.58 - $9.94 $82,819 - $108,604	-10,926 Closed	0 $0
Q4 2018 Jan 15, 2019	BUY	$7.16 - $16.21 $78,230 - $177,110	10,926 New	10,926 $84,000

466

63.8M

5.76M

3.4M

Ticker VKTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,688,496
Market Cap $2.6B
Description
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...

Get notified when there are updates to the investment portfolio of Fox Run Management, L.L.C., based on Form 13F filings with the SEC.

Stay updated on Fox Run Management, L.L.C. with notifications on news.